Total submissions: 9
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Invitae | RCV000465893 | SCV000563473 | benign | Neurofibromatosis, type 2 | 2024-01-30 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV000568714 | SCV000674126 | likely benign | Hereditary cancer-predisposing syndrome | 2017-08-07 | criteria provided, single submitter | clinical testing | This alteration is classified as likely benign based on a combination of the following: seen in unaffected individuals, population frequency, intact protein function, lack of segregation with disease, co-occurrence, RNA analysis, in silico models, amino acid conservation, lack of disease association in case-control studies, and/or the mechanism of disease or impacted region is inconsistent with a known cause of pathogenicity. |
Gene |
RCV000121646 | SCV000714463 | likely benign | not specified | 2018-01-24 | criteria provided, single submitter | clinical testing | This variant is considered likely benign or benign based on one or more of the following criteria: it is a conservative change, it occurs at a poorly conserved position in the protein, it is predicted to be benign by multiple in silico algorithms, and/or has population frequency not consistent with disease. |
ARUP Laboratories, |
RCV001171722 | SCV001158311 | likely benign | not provided | 2021-02-05 | criteria provided, single submitter | clinical testing | |
Ce |
RCV001171722 | SCV001334553 | likely benign | not provided | 2023-12-01 | criteria provided, single submitter | clinical testing | NF2: BP4 |
Genome- |
RCV000465893 | SCV002044927 | benign | Neurofibromatosis, type 2 | 2021-11-07 | criteria provided, single submitter | clinical testing | |
Sema4, |
RCV000568714 | SCV002528187 | benign | Hereditary cancer-predisposing syndrome | 2021-07-18 | criteria provided, single submitter | curation | |
All of Us Research Program, |
RCV000465893 | SCV004821923 | benign | Neurofibromatosis, type 2 | 2023-12-13 | criteria provided, single submitter | clinical testing | |
ITMI | RCV000121646 | SCV000085844 | not provided | not specified | 2013-09-19 | no assertion provided | reference population |